Patents by Inventor Jibiao WANG

Jibiao WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20240376081
    Abstract: Provided is a polymorph and application of a pyrimidine derivative and a pharmaceutically acceptable salt thereof. The polymorph and application of the pyrimidine derivative that is an A2A/A2B dual receptor antagonist having the chemical name 3-(4-amino-5-fluoro-6-(1-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)pyrimidine-2-yl)-2-methylbenzonitrile and the pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2022
    Publication date: November 14, 2024
    Inventors: Shuangni ZHAO, Taotao JIANG, Jibiao WANG, Tao TAO
  • PHARMACEUTICALLY ACCEPTABLE SALT OF MOR RECEPTOR AGONIST, AND POLYMORPH THEREOF AND USE THEREOF
    Publication number: 20240317761
    Abstract: Disclosed are a pharmaceutically acceptable salt of an MOR receptor agonist, and a polymorph thereof and the use thereof. Specifically, disclosed are a pharmaceutically acceptable salt of (4S,6S)-6-isopropyl-N-(2-((R)-9-(pyridin-2yl)-6-oxa spiro[4.5]decyl-9-yl)ethyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-4-amine, and a polymorph thereof and the use thereof. In addition, further disclosed are a pharmaceutical composition containing the pharmaceutically acceptable salt of the compound or the polymorph thereof, and the use thereof.
    Type: Application
    Filed: July 13, 2022
    Publication date: September 26, 2024
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaoling Dan, Taotao Jiang, Jibiao Wang, Jinlei Qiang
  • SOLID PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230149402
    Abstract: The present invention relates to a solid pharmaceutical preparation and a preparation method therefor. Specifically, disclosed are a solid pharmaceutical preparation that comprises an orexin receptor antagonist compound and a preparation method therefor, the solid pharmaceutical preparation comprising an active ingredient of a compound represented by formula I, a filler, a binder, a disintegrant, and a lubricant. The solid pharmaceutical preparation has good dissolution, stability and in vivo bioavailability.
    Type: Application
    Filed: April 14, 2021
    Publication date: May 18, 2023
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Taotao JIANG, Jibiao WANG, Han YANG, Li LI, Zhaoling DAN, Keyi ZHU, Zhenya ZENG, Bo SU, Xi CHEN
  • PHARMACEUTICALLY ACCEPTABLE SALTS OF BENZODICYCLOALKANE DERIVATIVE, POLYMORPHIC SUBSTANCE THEREOF, AND APPLICATION THEREOF
    Publication number: 20210087156
    Abstract: The present invention provides a pharmaceutically acceptable salt of benzodicycloalkane derivative and a polymorph thereof, and an application thereof. Specifically, the present invention provides a polymorph of benzobicyclic alkane derivative or a pharmaceutically acceptable salt thereof, and an application thereof. Furthermore, the present invention discloses a pharmaceutical composition of the compound and an application thereof.
    Type: Application
    Filed: April 23, 2019
    Publication date: March 25, 2021
    Inventors: Zhaoling DAN, Taotao JIANG, Jibiao WANG, Keyi ZHU
  • Sodium ion channel inhibitors and pharmaceutically acceptable salts and polymorphs thereof and uses thereof
    Patent number: 10947202
    Abstract: The present disclosure discloses sodium ion channel inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof. Specifically, the present disclosure discloses a polymorph of a compound of formula (X) and a preparation method thereof. The preparation method of the present disclosure is simple in operation and suitable for industrialization. The polymorph prepared by the preparation method has advantages of good stability, low hygroscopicity and high water solubility.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: March 16, 2021
    Inventors: Zheng Wang, Taotao Jiang, Jibiao Wang
  • SODIUM ION CHANNEL INHIBITORS AND PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF AND USES THEREOF
    Publication number: 20200048209
    Abstract: The present disclosure discloses sodium ion channel inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof. Specifically, the present disclosure discloses a polymorph of a compound of formula (X) and a preparation method thereof. The preparation method of the present disclosure is simple in operation and suitable for industrialization. The polymorph prepared by the preparation method has advantages of good stability, low hygroscopicity and high water solubility.
    Type: Application
    Filed: October 8, 2019
    Publication date: February 13, 2020
    Inventors: Zheng WANG, Taotao JIANG, Jibiao WANG